New Drug Futures (Vaccines)
Products that could change the Pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the vaccines sector. The report includes unique sales forecasts by major product. |
|
| Keywords: We estimate that vaccines generated sales of over US$10.6 billion in 2005, with over 50% derived from traditional, domestic paediatric vaccines and the development of novel vaccines that can command p | |
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
Publication Date: 19th May 2006
Contents:
NEW DRUG FUTURES
CURRENT MARKET SIZE 1
Vaccine Sales breakdown and forecasts 3
ADDRESSABLE PATIENT POPULATION 4
PAEDIATRIC VACCINES 5
ROTAVIRUS5
ADULT VACCINES 6
ZOSTER.VIRUS6
CERVICAL CANCER VACCINES 7
LUNG CANCER VACCINES 8
PROSTATE CANCER VACCINES 9
CURRENT TREATMENTS 10
VACCINE SALES DRIVERS 11
VACCINE SALES BREAKERS 12
FUTURE TREATMENTS 13
MARKET DYNAMICS - WINNERS & LOSERS 20
KEY VACCINE LAUNCHES BY 2010 21
KEY EVALUATION CRITERIA 22
KEY VACCINE LAUNCHES BY 2010 23
Cervarix.(GlaxoSmithKline/MedImmune23
Novelty/rationale for mechanism of action 23
Proof of concept/clinical data 23
Management / clinical expertise 24
Competition within the marketplace/gaining share of voice 24
Risks associated with developing a drug within a therapeutic class 24
Filings & Approvals 24
Sales forecasts and assumptions 25
Competitor Ratio Analysis 25
Gardasil.(Merck.&.Co/sanofi.pasteur25
Novelty/rationale for mechanism of action 25
Proof of concept/clinical data 25
Management / clinical expertise 26
Competition within the marketplace/gaining share of voice 26
Risks associated with developing a drug within a therapeutic class 26
Filings & Approvals 27
Sales forecasts and assumptions 27
Competitor Ratio Analysis 27
GVAX.(Cell.Genesys27
Novelty/rationale for mechanism of action 27
Proof of concept/clinical data 28
Management/clinical expertise 28
Competition within the marketplace/gaining share of voice 29
Risks associated with developing a drug within a therapeutic class 29
Filings and approval 29
Sales forecasts and assumptions 29
Competitor Ratio Analysis 30
L-BLP25.(Biomira/Merck.KGaA30
Novelty/rationale for mechanism of action 30
Proof of concept/clinical data 30
Management/clinical expertise 31
Competition within the marketplace/gaining share of Voice 31
Risks associated with developing a drug within a therapeutic class 31
Filings & Approvals 31
Sales forecasts and assumptions 32
Competitor Ratio Analysis 32
Provenge.(Dendreon33
Novelty/rationale for mechanism of action 33
Proof of concept/clinical data 33
Management/clinical expertise 34
Risks associated with developing a drug within a therapeutic class 34
Filings and approval 35
Sales forecasts and assumptions 35
Competitor Ratio Analysis 35
Rotarix.(GlaxoSmithKline/Avant.Immunotherapeutics36
Novelty/rationale for mechanism of action 36
Proof of concept/clinical data 36
Management and clinical expertise 36
Competition within the marketplace/ gaining share of voice 36
Risks associated with developing a drug within a therapeutic class 37
Filings & Approvals 37
Sales forecasts and assumptions 37
Competitor Ratio Analysis 38
Rotateq.(Merck.&.Co38
Novelty/rationale for mechanism of action 38
Proof of concept/clinical data 38
Management and clinical expertise 38
Competition within the marketplace/ gaining share of voice 39
Risks associated with developing a drug within a therapeutic class 39
Filings & Approvals 39
Sales forecasts and assumptions 39
Competitor Ratio Analysis 40
Streptorix.(GlaxoSmithKline/MedImmune40
Novelty/rationale for mechanism of action 40
Proof of concept/clinical data 40
Management/clinical expertise 41
Competition within the marketplace/gaining share of voice 41
Risks associated with developing a drug within a therapeutic class 41
Filings and approval 41
Sales forecasts and assumptions 42
Competitor Ratio Analysis 42
Zostavax (Merck.&.Co43
Novelty/rationale for mechanism of action 43
Proof of concept/clinical data 43
Management / clinical expertise 43
Competition within the marketplace/gaining share of voice 43
Filings & Approvals 44
Sales forecasts and assumptions 44
Competitor Ratio Analysis 44
COMPETITOR RATIO ANALYSIS SUMMARY 45
COMPETITOR RATIO ANALYSIS – VACCINES 46
COMPETITOR RATIO ANALYSIS - COMPANIES 48